Peptide
Semaglutide
STEP 1 to STEP 5, SELECT, and roughly 15% mean weight loss in obesity without diabetes.
Eng Säit pro Medikament. Effektgréissten, Studien-Designs, an d'Populatiounen, an deenen si gemëss ginn.
Peptide
STEP 1 to STEP 5, SELECT, and roughly 15% mean weight loss in obesity without diabetes.
Dual agonist
SURMOUNT-1 and -2, sleep apnoea and heart failure, and about 21% mean weight loss.
Oral
Oral semaglutide and orforglipron — the same mechanism without the injection.
Intermittent fasting, time-restricted eating and meal timing, judged on the trial data.
Energy expenditure, insulin resistance and metabolic adaptation, without the folklore.
Diets, drugs, behaviour and maintenance — ranked by the strength of the evidence behind them.
Sleep, circadian rhythm and the wearables that claim to measure both.
Dës Säit gouf automatesch aus dem Englischen iwwersat. D'Zitéierungen an d'Zuelen sinn onverännert. Liesen Sie den englischen Original, wann et komisch liest. Liest den englischen Original